系统性红斑狼疮患者能否减少贝利尤单抗的剂量?
西班牙多中心回顾性纵向研究纳入324例接受贝利尤单抗治疗的SLE患者,29例(8.9%)减少剂量。减量后6个月和12个月分别有8.3%和13.6%失去缓解、8.7%和9.5%失去LLDAS(均无统计学显著性),12个月时使用糖皮质激素的患者显著减少但中位剂量更高。作者认为短期减量可行但部分患者可能出现临床或血清学活动度升高,建议减量后加强随访。
要点
- 324例接受贝利尤单抗治疗的SLE患者中29例(8.9%)减少剂量。
- 减量后6个月和12个月失去缓解分别为2/24例(8.3%)和3/22例(13.6%),失去LLDAS分别为2/23例(8.7%)和2/21例(9.5%),均无统计学显著性。
- 12个月时使用糖皮质激素的患者显著减少,但中位剂量较基线升高(5[0.62-8.75] vs 2.5[0-5])。
核心结论
- 作者认为在相当比例的患者中贝利尤单抗剂量可以减少,至少短期内疾病活动度无相关变化,且多数患者维持减量剂量。
- 作者指出部分患者可能观察到临床或血清学活动度升高,因此建议减量后加强随访。
研究设计与样本
- 西班牙多中心回顾性纵向研究,纳入324例接受贝利尤单抗治疗的SLE患者,记录减量前后(6-12个月)的疾病活动度、治疗和结局数据并进行比较。
主要发现
- 29例(8.9%)患者减少剂量,其中9例接受皮下贝利尤单抗者延长给药间隔、6例接受静脉贝利尤单抗者延长给药间隔、16例减少每次给药剂量。
- 减量前15/26例(57.7%)处于缓解(2021 DORIS),23/26例(88.5%)处于LLDAS。
- 减量后6个月和12个月分别有2/24例(8.3%)和3/22例(13.6%)失去缓解,差异无统计学显著性。
- 减量后6个月和12个月分别有2/23例(8.7%)和2/21例(9.5%)失去LLDAS,差异无统计学显著性。
- 12个月时使用糖皮质激素的患者显著减少,但12个月时中位糖皮质激素剂量高于基线(5[0.62-8.75] vs 2.5[0-5])。
临床怎么用
- 作者建议减量后加强随访。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aims of this study were to investigate the prevalence of dose reduction in patients with SLE treated with belimumab (BEL) in Spain, analyse treatment modalities, and determine impact on control of disease activity. METHODS: Retrospective longitudinal and multicentre study of SLE patients treated with BEL. Data on disease activity, treatments and outcomes were recorded before and after reduction (6-12 months), and they were compared. RESULTS: A total of 324 patients were included. The dose was reduced in 29 patients (8.9%). The dosing interval was increased in nine patients receiving subcutaneous BEL and in six patients receiving intravenous BEL. The dose per administration was reduced in 16 patients. Pre-reduction status was remission (2021 DORIS) in 15/26 patients (57.7%) and LLDAS in 23/26 patients (88.5%). After reduction, 2/24 patients (8.3%) and 3/22 patients (13.6%) lost remission at 6 months and 12 months, respectively [not statistically significant (NS)]. As for LLDAS, 2/23 patients (8.7%) and 2/21 patients (9.5%) lost their status at 6 and 12 months, respectively (NS). Significantly fewer patients were taking glucocorticoids (GCs) at their 12-month visit, although the median dose of GCs was higher at the 12-month visit (5 [0.62-8.75] vs 2.5 [0-5] at baseline). CONCLUSION: Doses of BEL can be reduced with no relevant changes in disease activity-at least in the short term-in a significant percentage of patients, and most maintain the reduced dose. However, increased clinical or serologic activity may be observed in some patients. Consequently, tighter post-reduction follow-up is advisable.
引用
- Rua-Figueroa I, Altabás-González I, Mouriño C, et al. Can the dose of belimumab be reduced in patients with systemic lupus erythematosus? Rheumatology (Oxford). 2025. PMID: 38741198. doi:10.1093/rheumatology/keae270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。